scholarly journals Progressive valvular calcifications with critical aortic stenosis in a 25-year-old woman with end-stage renal disease on haemodialysis: a case report

2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Christina Stolzenburg Oxlund ◽  
Helle Hansen ◽  
Stinus Hansen ◽  
Allan Rohold

Abstract Background  The increased risk of cardiovascular morbidity and mortality in chronic kidney disease (CKD) and end-stage renal disease (ESRD) seems particularly pronounced in patients with concomitant aortic and mitral valvular calcifications. Valvular calcification (VC) is accelerated in patients with CKD and even more so with ESRD and haemodialysis (HD) due to premature endothelial cell dysfunction. Mineral and bone disorder (CKD-MBD) is a common complication of CKD/ESRD and may play a pivotal role in VC. Case summary  A 25-year-old woman with congenital hypoplastic kidneys and ESRD on HD from the age of 19 was admitted to the emergency department suffering from chest pain and dyspnoea. Transthoracic echocardiogram (TTE) revealed critical aortic stenosis (AS) with indexed aortic valve area 0.4 cm2/m2, a mean gradient 58 mmHg and a moderate mitral stenosis with a mean gradient 6–8 mmHg developed over the course of 2 years, as a normal TTE was performed at that time. During HD, the patient had longstanding alterations in calcium and phosphate metabolism including secondary hyperparathyroidism that eventually progressed into tertiary hyperparathyroidism. Efforts were made to treat CKD-MBD but patient compliance was low. Subtotal parathyroidectomy was performed 6 months prior to admission. The patient had dual mechanical valve replacement. Discussion  Valvular calcification is common in patients with CKD/ESRD and in particular in patients on HD. Rapid progression of valve disease in this case may be related to the combination of low patient adherence and sustained disturbed calcium and phosphate metabolism with tertiary hyperparathyroidism. Transthoracic echocardiogram should be performed in patients on HD even with minor suspicion of VC and in patients with low adherence and disturbance of calcium and phosphate metabolism.

1996 ◽  
Vol 135 (4) ◽  
pp. 617-622 ◽  
Author(s):  
Ch.C. ZOUBOULIS ◽  
U. BLUME-PEYTAVI ◽  
Th. LENNERT ◽  
P.G. STAVROPOULOS ◽  
A. SCHWARZ ◽  
...  

Author(s):  
Amgad Mentias ◽  
Milind Y. Desai ◽  
Marwan Saad ◽  
Phillip A. Horwitz ◽  
James D. Rossen ◽  
...  

Background: Patients with end-stage renal disease on hemodialysis (ESRD-HD) and aortic stenosis have poor prognosis. The role of transcatheter aortic valve replacement (TAVR) in this high-risk population is debated. Methods: We compared the outcomes among ESRD-HD Medicare beneficiaries who were managed with TAVR, surgical AVR (SAVR), or conservative management for aortic stenosis between 2015 and 2017, using overlap propensity score weighting analysis to control for differences in treatment assignment. The primary outcome was all-cause mortality and was compared between treatment groups as well as to age-sex matched mortality for ESRD-HD in the US population. Secondary outcomes included trend of heart failure hospitalizations. Results: A total of 8107 ESRD-HD patients with aortic stenosis were included, 4130 (50%) underwent TAVR, 2565 (31.6%) underwent SAVR, and 1412 (17.4%) were managed conservatively. TAVR patients had more comorbidities and higher frailty compared with the other 2 groups. Thirty-day mortality was lower with TAVR compared with SAVR (4.6% versus 12.8%, P <0.01). After a median follow-up of 465 days (interquartile range, 261–759), on overlap propensity score weighting analysis, there was no difference in mortality between TAVR and SAVR (adjusted hazard ratio, 1.02 [95% CI, 0.91–1.15], P =0.7), and mortality was lower with TAVR compared with conservative management (adjusted hazard ratio, 0.53 [95% CI, 0.47–0.60], P <0.001). Standardized mortality ratios with TAVR, SAVR, and conservative management compared with age-sex matched ESRD-HD US population were 1.24, 1.27, and 1.83, respectively. The rate of heart failure admissions declined after TAVR (incidence rate ratio, 0.55 [95% CI, 0.48–0.62], P <0.001) and SAVR (incidence rate ratio, 0.76 [95% CI, 0.65–0.88], P <0.001). Conclusions: In ESRD-HD patients with aortic stenosis, mortality was lower in the short-term with TAVR compared with SAVR but comparable in the mid-term. AVR is associated with an improvement in survival and reduction in heart failure hospitalizations compared with conservative management.


2016 ◽  
Vol 117 (12) ◽  
pp. 1972-1977 ◽  
Author(s):  
Darae Kim ◽  
Chi Young Shim ◽  
Geu-Ru Hong ◽  
In Jeong Cho ◽  
Hyuk-Jae Chang ◽  
...  

1996 ◽  
Vol 135 (4) ◽  
pp. 617-622 ◽  
Author(s):  
Ch.C. ZOUBOULIS ◽  
U. BLUME-PEYTAVI ◽  
Th. LENNERT ◽  
P.G. STAVROPOULOS ◽  
A. SCHWARZ ◽  
...  

2017 ◽  
Vol 89 (6) ◽  
pp. 1109-1115 ◽  
Author(s):  
Jose F. Condado ◽  
Aneel Maini ◽  
Bradley Leshnower ◽  
Vinod Thourani ◽  
Jessica Forcillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document